carvedilol 25mg film-coated tablets
aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - carvedilol - film-coated tablet - carvedilol 25 mg - beta blocking agents
cardicor 1.25 mg film-coated tablets
merck serono (ireland) limited - bisoprolol hemifumarate - film-coated tablet - 1.25 milligram(s) - beta blocking agents, selective; bisoprolol
cardicor 10 mg film-coated tablets
merck serono (ireland) limited - bisoprolol hemifumarate - film-coated tablet - 10 milligram(s) - beta blocking agents, selective; bisoprolol
cardicor 2.5 mg film-coated tablets
merck serono (ireland) limited - bisoprolol hemifumarate - film-coated tablet - 2.5 milligram(s) - beta blocking agents, selective; bisoprolol
cardicor 3.75 mg film-coated tablets
merck serono (ireland) limited - bisoprolol hemifumarate - film-coated tablet - 3.75 milligram(s) - beta blocking agents, selective; bisoprolol
cardicor 5 mg film-coated tablets
merck serono (ireland) limited - bisoprolol hemifumarate - film-coated tablet - 5 milligram(s) - beta blocking agents, selective; bisoprolol
cardicor 7.5 mg film-coated tablets
merck serono (ireland) limited - bisoprolol hemifumarate - film-coated tablet - 7.5 milligram(s) - beta blocking agents, selective; bisoprolol
sertraline 100 mg film-coated tablets
accord healthcare ireland ltd. - sertraline - film-coated tablet - 100 milligram(s) - selective serotonin reuptake inhibitors; sertraline
sertraline 50 mg film-coated tablets
accord healthcare ireland ltd. - sertraline - film-coated tablet - 50 milligram(s) - selective serotonin reuptake inhibitors; sertraline
vfend 200 mg film-coated tablets
pfizer pfe pharmaceuticals israel ltd - voriconazole - film coated tablets - voriconazole 200 mg - voriconazole - treatment of: - invasive aspergillosis, - fluconazole-resistant serious invasive candida infections (including c. krusei),- serious fungal infections caused by scedosporium spp. and fusarium spp.- vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - treatment of candidemia in non neutropenic patients.- prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.